Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
viernes, octubre 30
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Boston Scientific Corp
BSX
NYSE
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$42.55
-0.14
-0.33%
Últ. Act.: Oct 29, 7:59 PM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Ganancias:
Los beneficios de Q3 2026 se publicaron el mié oct 28th, antes de la apertura del mercado
Conferencia telefónica:
La conferencia telefónica más reciente comenzó a las 8:00 a. m., hace 2 días
Haz clic para ver el webcast
Boston Scientific Financials
Boston Scientific (BSX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
These Analysts Revise Their Forecasts On Boston Scientific After Q3 Results
Boston Scientific beat Q3 estimates but cut FY26 guidance; Q4 forecasts missed expectations. Analysts adjusted price targets.
Avi Kapoor
Boston Scientific Overshadowed by Hackers, Headwinds, and Lower Guidance
Boston Scientific slips after a cyber fallout offsets a Q3 consensus beat. Management targets a 2027 cycle trough and 2030 expansion.
Vandana Singh
PRO
Boston Scientific Lowers FY2026 Adj EPS Guidance from $3.28-$3.32 to $3.16-$3.18 vs $3.23 Est; Lowers FY2026 Sales Guidance from $21.178B-$21.379B to $20.927B vs $21.143B Est
Boston Scientific (NYSE:BSX) lowers FY2026 Adj EPS guidance from $3.28-$3.32 to $3.16-$3.18 vs $3.23 analyst estimate. Lowers FY2026 sales outlook from $21.178 billion-$21.379 billion to $20.927 billion vs $21.143
Benzinga Newsdesk
PRO
Boston Scientific Sees Q4 Adj EPS $0.77-$0.79 vs $0.84 Est; Sees Sales $5.127B-$5.233B vs $5.404B Est
Boston Scientific (NYSE:BSX) is looking for Q4 Adj EPS of $0.77-$0.79 vs $0.84 analyst estimate. sees sales of $5.127 billion-$5.233 billion vs $5.404 billion analyst estimate.
Benzinga Newsdesk
PRO
Boston Scientific Q3 Adj. EPS $0.73 Beats $0.72 Estimate, Sales $5.138B Beat $5.046B Estimate
Boston Scientific (NYSE:BSX) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.72 by 1.39 percent. This is a 2.67 percent decrease over earnings of $0.75 per share from the
Benzinga Newsdesk
Microsoft, Alphabet On Deck Wednesday As AI Spending, Cloud Growth Face Test
Microsoft and Alphabet headline Wednesday’s reports, with investors weighing whether AI infrastructure spending is translating into durable cloud and advertising growth. GE Vernova, Amphenol, Banco Santander, UBS Group
Benzinga Insights
